icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
Y1Y4tAp7YAXdKSSZ